ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- A novel non-invasive approach monitoring skeletal stem cell function throughJournal of orthopaedic translation · 2026Article
- Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Increasing the activity output and optimization of automated radiosynthesis [EJNMMI radiopharmacy and chemistry · 2026Article
- Progress in the application of 68Ga-Pentixafor PET/CT in lung cancer: a review.Oncology reviews · 2026Review
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
- The Role of 68Ga-Pentixafor and 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in a Case of Multiple Myeloma.Cureus · 2026Article
- CXCR4-directed PET withEndocrine · 2025Article
- Article
- CXCR4 as a therapeutic target in acute myeloid leukemia.Leukemia · 2024Review
- Advances in PET Imaging of the CXCR4 Receptor: [Seminars in nuclear medicine · 2024Review
- Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.Korean journal of radiology · 2023Review
- Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.Journal of medicinal chemistry · 2023Article
- CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022Review
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- Role of Peptides in Diagnostics.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.